Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Seres Therapeutics, Inc.MCRB · Entity 7191 | See Remarks | February 04, 2021 | February 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Seres Therapeutics, Inc.
Report date February 04, 2021 · Filed February 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 12,000 |
Reported balance
After 2021-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-04 · Grant · Acquired 12,000 · Balance 12,000 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units will vest and settle as to 25% of the restricted stock units on March 15, 2022. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.34 · Expires 2031-02-03 | Direct | 24,000 |
Reported balance
After 2021-02-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-04 · Grant · Acquired 24,000 · Balance 24,000 F3: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2: The restricted stock units will vest and settle as to 25% of the restricted stock units on March 15, 2022. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter.
F3: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2021 Filed Feb 8, 2021 23:55 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $26.34 | $0.00 |
DisclosureSEC source: 0000899243-21-005254 · doc4.xml · derivative · entry 2 Chapman Marcus · CIK 0001770404 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2031-02-03 F3 · derivative.exercise_date: The option will vest as to 25% of the shares on February 4, 2022. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| February 04, 2021 Filed Feb 8, 2021 23:55 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005254 · doc4.xml · derivative · entry 1 Chapman Marcus · CIK 0001770404 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2 · derivative.exercise_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on March 15, 2022. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. F2 · derivative.expiration_date: The restricted stock units will vest and settle as to 25% of the restricted stock units on March 15, 2022. The remainder of the restricted stock units will vest and settle in 12 equal quarterly installments thereafter. Read SEC document |
| April 22, 2020 Filed Apr 24, 2020 20:10 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 18,596 | $0.00 Strike: $3.74 | $0.00 |
DisclosureSEC source: 0000899243-20-011277 · doc4.xml · derivative · entry 1 Chapman Marcus · CIK 0001770404 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,596 Underlying: Common Stock · 18,596 shares Expires 2030-04-21 F1 · derivative.exercise_date: The option will vest in full on April 22, 2021. Read SEC document |
| January 29, 2020 Filed Jan 31, 2020 21:07 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | GrantSTOCK OPTION (RIGHT TO BUY) · Derivative | 125,000 | $0.00 Strike: $3.30 | $0.00 |
DisclosureSEC source: 0000899243-20-002422 · doc4.xml · derivative · entry 1 Chapman Marcus · CIK 0001770404 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2030-01-28 F1 · derivative.exercise_date: The option will vest as to 25% of the shares on January 29, 2021. The remainder of the shares will vest in 12 equal quarterly installments thereafter. Read SEC document |
| November 22, 2019 Filed Nov 25, 2019 21:32 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | SaleCommon Stock | 3,400 | $3.91 | $13,296.72 |
DisclosureSEC source: 0000899243-19-028069 · doc4.xml · nonDerivative · entry 2 Chapman Marcus · CIK 0001770404 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,600 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan, dated June 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.90 to $3.93. The reporting person undertakes to provide Seres Therapeutics, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2019 Filed Nov 25, 2019 21:32 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionRestricted Stock Units · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028069 · doc4.xml · derivative · entry 3 Chapman Marcus · CIK 0001770404 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4 · derivative.exercise_date: The restricted stock units vested in full on November 1, 2019. F4 · derivative.expiration_date: The restricted stock units vested in full on November 1, 2019. Read SEC document |
| November 01, 2019 Filed Nov 25, 2019 21:32 UTC | Seres Therapeutics, Inc. MCRB · Entity 7191 | Exercise / conversionCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-028069 · doc4.xml · nonDerivative · entry 1 Chapman Marcus · CIK 0001770404 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.